American Express, Eni On Deck Friday As Spending, Energy Demand Face Test

?xml encoding="utf-8" ?>

American Express headlines Friday’s reports, with premium-card spending and consumer resilience the central questions after a sharp year-to-date stock decline. Eni SpA, SLB, Infosys, First Citizens BancShares, Rogers Communications, Dr. Reddy’s Laboratories, Booz Allen Hamilton, Autoliv and Balchem also report before the open.

Key Reports Before The Bell

American Express (NYSE:AXP)/a> — Q3 — 7:00 a.m. ET

li>EPS: $4.49 est. vs. $4.14 a year ago (+8%)/li>li>Revenue: $20.12 billion est. vs. $18.43 billion a year ago (+9%)/li>li>Stock: +7.5% past month, -12.1% YTD, 16.3% below its 52-week high/li>li>Analyst view: Buy consensus, $363 target (16 analysts)/li>

American Express has beaten estimates in seven of its past eight quarters, but investors will be focused on whether premium-card spending and customer acquisition can sustain growth as the stock remains below its 52-week high. In Q2, it beat on EPS but missed revenue. On its July call, management said it was raising full-year revenue growth guidance to 10% while maintaining its EPS outlook and investing in Platinum products and European dining. Morgan Stanley maintained its Equal-Weight rating while lowering its target to $380 from $382 on Oct. 12.

Eni SpA (NYSE:E)/a> — Q3 — 5:00 a.m. ET

li>EPS: $1.92 est. vs. $0.95 a year ago (+102%)/li>li>Revenue: $22.74 billion est. vs. $23.62 billion a year ago (-4%)/li>li>Stock: +8.4% past month, +56.6% YTD, 0.7% below its 52-week high/li>

The energy company enters the report with its stock near its 52-week high after a strong year-to-date advance, putting operational execution and resilience amid geopolitical volatility at the center of the readout. In Q2, it missed on both EPS and revenue. On its July call, management highlighted geographic diversification and proprietary technologies as key sources of resilience amid geopolitical volatility.

SLB (NYSE:SLB)/a> — Q3 — 7:00 a.m. ET

li>EPS: $0.62 est. vs. $0.69 a year ago (-10%)/li>li>Revenue: $9.27 billion est. vs. $8.93 billion a year ago (+4%)/li>li>Stock: -4.5% past month, +29.1% YTD, 17.9% below its 52-week high/li>li>Analyst view: Buy consensus, $64 target (14 analysts)/li>

SLB has beaten estimates in five of its past eight quarters, with investors looking for evidence that international activity, Production Systems and Digital can offset pressure on the stock after its recent pullback. In Q2, it beat on both EPS and revenue. On its July call, management pointed to international growth, a North American rebound and strong momentum in Production Systems and Digital. Citigroup maintained its Buy rating while lowering its target to $62 from $63 on Oct. 19.

Infosys (NYSE:INFY)/a> — Q2 — 7:00 a.m. ET

li>EPS: $0.21 est. vs. $0.20 a year ago (+5%)/li>li>Stock: +22.8% past month, -25.9% YTD, 56.0% below its 52-week high/li>li>Analyst view: Hold consensus, $11 target (7 analysts)/li>

Infosys has beaten estimates in just three of its past eight quarters, and the focus is whether AI-services growth can offset client terminations, pricing pressure and a stock still far below its 52-week high. In Q1, it missed on both EPS and revenue. On its July call, management said AI services were contributing a growing share of revenue while appointing Ashish Dash as CEO-designate ahead of Salil Parekh’s planned transition. BMO Capital maintained its Market Perform rating while lowering its target to $12 from $13 in July.

First Citizens BancShares (NASDAQ:FCNCA)/a> — Q3 — 6:31 a.m. ET

li>EPS: $46.11 est. vs. $44.62 a year ago (+3%)/li>li>Revenue: $2.23 billion est. vs. $2.43 billion a year ago (-8%)/li>li>Stock: +6.8% past month, +1.5% YTD, 4.9% below its 52-week high/li>li>Analyst view: Hold consensus, $2,286 target (8 analysts)/li>

First Citizens BancShares has beaten estimates in six of its past eight quarters, with loan demand, deposit trends and the durability of its specialized banking franchises likely to shape the reaction. In Q2, it beat on both EPS and revenue. On its July call, management highlighted 1.6% sequential loan growth and a 1.5% increase in period-end deposits, led by Global Fund Banking, Tech and Healthcare Banking and Middle Market Banking. JP Morgan maintained its Neutral rating while lowering its target to $2,300 from $2,450 on Oct. 1.

Rogers Communications (NYSE:RCI)/a> — Q3 — 7:00 a.m. ET

li>EPS: $0.85 est. vs. $1.00 a year ago (-15%)/li>li>Revenue: $3.79 billion est. vs. $3.88 billion a year ago (-2%)/li>li>Stock: -0.6% past month, -12.4% YTD, 19.4% below its 52-week high/li>li>Analyst view: Hold, $35 target (1 analyst)/li>

Rogers Communications has beaten estimates in seven of its past eight quarters, but investors will be watching whether service growth, free cash flow and its sports-media strategy can reverse a stock that remains well below its 52-week high. In Q2, it beat on EPS but missed revenue. On its July call, management reported higher service revenue and free cash flow while outlining strategic sports-media initiatives.

Dr Reddy’s Laboratories (NYSE:RDY)/a> — Q2 — 7:00 a.m. ET

li>EPS: $0.16 est. vs. $0.19 a year ago (-16%)/li>li>Revenue: $980.6 million est. vs. $992.0 million a year ago (-1%)/li>li>Stock: +6.7% past month, -5.9% YTD, 15.6% below its 52-week high/li>li>Analyst view: Buy (1 analyst)/li>

Dr. Reddy’s Laboratories has beaten estimates in four of its past eight quarters, with the test centered on whether new product launches and North American growth can offset weaker lenalidomide sales and semaglutide-related pressure. In Q1, it missed on both EPS and revenue. On its July call, management said the base business was growing at a double-digit pace across key regions despite lower lenalidomide sales and semaglutide API challenges.

Booz Allen Hamilton Holding (NYSE:BAH)/a> — Q2 — 6:45 a.m. ET

li>EPS: $1.47 est. vs. $1.49 a year ago (-1%)/li>li>Revenue: $2.81 billion est. vs. $2.89 billion a year ago (-3%)/li>li>Stock: +4.0% past month, -6.7% YTD, 27.9% below its 52-week high/li>li>Analyst view: Hold consensus, $87 target (10 analysts)/li>

Booz Allen Hamilton has beaten estimates in six of its past eight quarters, while the key question is whether cyber and DefenseTech momentum can offset ongoing weakness in the civil portfolio. In Q1, it beat on EPS but missed revenue. On its July call, management said civil revenue was pressured by contract roll-offs and fewer new program starts while it invested in autonomy, AI, quantum computing and the Ultra Mission Solutions acquisition. Truist Securities upgraded the stock to Buy from Hold with an $85 target on Oct. 8.

Autoliv (NYSE:ALV)/a> — Q3 — 6:00 a.m. ET

li>EPS: $2.23 est. vs. $2.32 a year ago (-4%)/li>li>Revenue: $2.71 billion est. vs. $2.71 billion a year ago/li>li>Stock: +3.1% past month, +0.3% YTD, 10.2% below its 52-week high/li>li>Analyst view: Hold consensus, $129 target (5 analysts)/li>

Autoliv has beaten estimates in six of its past eight quarters, and investors will be looking for evidence that record operating performance and cost reductions can withstand geopolitical and auto-production headwinds. In Q2, it beat the revenue estimate. On its July call, management highlighted record sales and adjusted operating income while pointing to cooperation agreements with Chinese vehicle manufacturers. RBC Capital maintained its Outperform rating while lowering its target to $146 from $147 on Oct. 12.

Balchem (NASDAQ:BCPC)/a> — Q3 — 7:00 a.m. ET

li>EPS: $1.53 est. vs. $1.35 a year ago (+13%)/li>li>Revenue: $289.2 million est. vs. $267.6 million a year ago (+8%)/li>li>Stock: +2.4% past month, +12.3% YTD, 6.3% below its 52-week high/li>li>Analyst view: Buy, $215 target (1 analyst)/li>

Balchem has beaten estimates in six of its past eight quarters, with the focus on whether broad-based demand across human nutrition, animal nutrition and specialty products can extend its record operating momentum. In Q2, it beat on both EPS and revenue. On its July call, management highlighted double-digit sales and adjusted EBITDA growth across all three segments. The setup favors a test of whether recent market-penetration gains can continue without margin pressure becoming the larger issue.

Also Reporting Before The Bell

li>Gentex (NASDAQ:GNTX)/a> — $0.50 EPS on $669.5 million revenue/li>li>Rithm Capital (NYSE:RITM)/a> — $0.50 EPS on $1.47 billion revenue/li>li>Flagstar Bank NA (NYSE:FLG)/a> — $0.07 EPS on $543.1 million revenue/li>li>First Hawaiian (NASDAQ:FHB)/a> — $0.59 EPS on $229.1 million revenue/li>

Plus 4 companies valued between $100 million and $2 billion, including Gorman-Rupp, Preferred Bank and World Acceptance.

Also Reporting After The Bell

Plus 2 companies valued between $100 million and $2 billion, including River City Bank and First Bank.

Benzinga Earnings Calendar